← Jade Biosciences, Inc. (JBIO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Jade Biosciences, Inc. (JBIO)
Pharmaceutical Preparations · market cap $990M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Jade Biosciences (JBIO) is a clinical-stage pharmaceutical company with 30 employees and a ~$1.03B market cap, built around a single disclosed asset, JADE101, currently in Phase 2 for IgA Nephropathy (IgAN). The company is pre-revenue, burning roughly $93M in R&D annually, and holds $311M in cash (~39 months of runway). The mechanism of action for JADE101 has not been publicly disclosed in the available facts.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2027-01-01Phase 1imp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| JADE101 | Phase 2 | IgA Nephropathy |
Price & technical context
3-month
-36.1%
6-month
-12.1%
12-month
+49.4%
52-wk range
$8.33–$26.85
vs 50-day MA
-30.0%
vs 200-day MA
-25.7%
Realized vol
72.1%
Max drawdown
-93.1%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for JBIO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.